36 years of Qilu pharmaceutical: realizing high-speed and steady development in the transformation of new and old kinetic energy

[China Pharmaceutical network enterprise news] every year, a small step, a big step in ten years Throughout the 36 year development process of Qilu pharmaceutical, there are not only hardships, but also many honors and achievements The concept of "only by emancipating the mind and innovating constantly, can enterprises realize sustainable development" has been running through the whole development process of Qilu pharmaceutical (36 years of Qilu pharmaceutical: achieving high-speed and steady development in the transformation of new and old driving forces photo source: Baidu photo) recently, the 11th provincial Party Congress just concluded issued a strong voice of "firmly grasp the goal of taking the lead, accelerate the construction of a strong province with strong economy and culture" "Highlighting transformation", "realizing innovation and development in Shandong", "strengthening innovation drive", "strengthening and optimizing the real economy", "adhering to world vision, international standards, Shandong's advantages, and actively creating a national new and old energy conversion pilot area" In the report of the Party Congress, such practical measures with a sense of the times can be seen everywhere In order to show the effect of the transformation of the new and old energy in our province, Qilu Evening News, Qilu one point, set up a special column of Shandong to read the transformation of the new and old energy, and reported the experience and practice of the transformation of the new and old energy of all kinds of enterprises Let's go into Qilu pharmaceutical and see her 36 years of innovation, breakthrough and transformation Looking at the 36 years of development of Qilu pharmaceutical, it is a history of high-speed and steady development of enterprises driven by scientific and technological innovation and continuous transformation of new and old driving forces In 1981, Comrade Li Botao was appointed secretary of the Party committee and director of the factory, and formally established the transformation from single animal vaccine to human medicine This major decision became a "new driving force" for the rapid and steady development of Qilu pharmaceutical for more than 30 years In the meantime, Qilu pharmaceutical takes a small step every year and a big step in ten years With an average annual growth rate of more than 20%, it has achieved a sustained leap forward development from small to large, from weak to strong If we say that since 1981, the company decided to implement the strategic transformation from animal vaccine to human medicine, which made the company enter a "long cycle" of new kinetic energy, the long cycle of new kinetic energy is divided into four sub cycles with a span of about ten years In the early 1980s, Mr Li Botao put forward the 36 word enterprise policy of "taking reform as the driving force, talent as the root, market as the leader, science and technology as the development, quality as the survival, and management as the benefit" This is a very advanced new development concept guided by the concept of market economy It was not until 1992 that the 14th National Congress of the CPC Central Committee established the general development policy of building a socialist market economy Achievements: we have successfully developed ampicillin sodium, cisplatin and carboplatin, new anticancer drugs, which have been successfully developed and put on the market New anticancer drugs have become an important field of our company's human drug products By 1990, the total output value had exceeded 100 million yuan, and the profits and taxes had exceeded 10 million yuan Suddenly, from a small factory on the verge of bankruptcy, it has become one of the 20 key enterprises with an output value of more than 100 million yuan in Jinan Behind the gorgeous turn is the "out of the system" pharmaceutical enterprises, which live in the iron plate and crack of the planned economy A successful exploration of the development mode points out the direction for the subsequent development of the enterprises The concept of "only by emancipating the mind and innovating constantly, can the enterprise realize sustainable development" is initially formed and runs through the whole development process of Qilu pharmaceutical Lay a solid foundation for steady growth (1991-2000) strategic direction: take product innovation as the guide, carry out domestic and foreign scientific research and development cooperation, ensure the company's products "R & D generation, production generation, reserve generation", increase R & D efforts, optimize product structure, launch new projects in the world, increase preparation project construction, and achieve steady growth of the company Achievements: Based on the successful transformation exploration in the early stage, the company quickly adapts to the transition reform from "plan" to "market" in the macro-economy, initially forms the pattern of "all big and high" products, and steps into the development period of "all dosage forms, multi specifications, large scale and high production capacity" A number of drugs are the first to be listed in China The product field covers many fields, such as anti-tumor, cardio cerebrovascular, anti infection, tumor auxiliary, gene engineering, etc the product structure is further optimized, with many products By 2000, the sales revenue was nearly 1 billion yuan, laying a solid foundation for the rapid development in the later period Leading the industry, testing water biomedicine, successfully developing and marketing the adjuvant anti-tumor drug Ribai, with a long-term market share, leading the Qilu biomedical industry Through the strategic direction of high-speed development (2001-2010): comprehensively and deeply promote the four strategies of market strategy, R & D strategy, boutique strategy and talent strategy; deeply cultivate the domestic market, grasp the opportunity, accelerate the international certification, fully develop the international market, connect the domestic and foreign markets, and explore the path of global development International certification is the access certificate for products to enter the international market Up to now, Qilu pharmaceutical has successively obtained the product certification and approval of the regulatory market of the United States, the European Union, Japan, Australia, Russia and other countries and regions Achievements: a number of heavyweight products have been listed; scale advantages are obvious: seven production bases have been built one after another, with multiple product capacity and market share in China and even in the world; product certification achievements are remarkable: domestic certification achievements remain advantages in the industry, and international certification continues to achieve good results; The company has entered a new stage of sustained, healthy and high-speed development, with an average annual growth rate of more than 20% in the industry; in 2010, the company achieved a sales revenue of 5 billion yuan Breakthrough and surpass the decisive future (2011 -) strategic direction: from the perspective of global development, fully integrate with the international community, comprehensively improve management level, and accelerate the global development strategy In depth cooperation with world pharmaceutical research institutions, establish scientific research team, aim at the forefront of the industry, accelerate innovative drug research and development, and seize the industry to the highest point We will continue to strengthen the research, development and imitation of large clinical varieties, break the monopoly, improve the clinical accessibility of drugs, and reduce the burden on patients and medical insurance funds In line with the trend of industrial development and with the help of national industrial policies, we will further consolidate the traditional advantages of chemical drugs and strengthen the expansion of biomedical industry Achievements: in 2014, the sales revenue exceeded 10 billion yuan, becoming the first private enterprise of over 10 billion yuan in Jinan In 2014 and 2015, it ranked in the top 10 of the top 100 pharmaceutical industries in China for two consecutive years Gefitinib, a blockbuster anti-cancer drug, was launched for the first time, breaking the monopoly and greatly reducing the burden on patients and medical insurance funds A number of biomedical R & D breakthroughs have been made The first phase of Jinan biomedical industrial park has been completed, and a two wheel drive pattern of chemical drugs and biomedical industry has been preliminarily formed, with full potential for enterprise development With the acceleration of globalization, many pharmaceutical products have entered the U.S and EU markets, and overseas R & D has been accelerated.